Monthly Newsletter

NovAlix today announces that it has entered into a multi-year research services agreement for chemistry with Janssen-Cilag, France, to support its drug discovery efforts.

Under the terms, NovAliX scientists will provide distant as well on-site chemistry support, optimally exploiting strong organic synthetic expertise and unique biophysical capabilities, to accelerate the drug discovery process. In addition the operational excellence of NovAliX allows to explore a complete new model by which the respective scientists work side by side for greater efficiency and scientific exchange and therefore promoting the concept of Open Innovation.

Stephan Jenn, president of NovAliX, said "he welcomes this significant chemistry discovery deal that acknowledges the quality of our science, technologies and organization".

About NovAliX SAS - www.novalix-pharma.com
Strasbourg, France based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing.

With proprietary unique SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.

NovAliX Group, a team of 120 scientists, is located in state-of-the-art laboratory facilities in Strasbourg-Illkirch (France) and Heidelberg (Germany)